Home » Topics » Regulatory » EMA

EMA
RSS

EC grants orphan drug status for S*BIO's SB-1518 in myelofibrosis

Oct. 20, 2010

EMA recommends approval of CTI's pediatric investigation plan for Pixuvri

Oct. 20, 2010

European orphan drug status for recombinant porcine factor VIII in hemophilia A

Oct. 20, 2010

EMA grants orphan drug status for forodesine in chronic lymphocytic leukemia

Oct. 19, 2010

EC grants orphan drug status for pralatrexate in Hodgkin's lymphoma

Oct. 19, 2010

European orphan drug status for NeuroSTAT in traumatic brain injury

Oct. 18, 2010

EMA approves Twynsta single pill combination for high blood pressure

Oct. 14, 2010

Tesetaxel receives EMA orphan drug status for gastric cancer

Oct. 14, 2010

Merck KGaA to appeal CHMP's opinion on cladribine tablets in MS

Oct. 11, 2010

CHMP recommends variation to terms of marketing authorization for Invega

Oct. 5, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...